[Drug therapy of depression: benefits and limits of blood levels of tricyclic antidepressants]

Details

Serval ID
serval:BIB_392CC5196F91
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
[Drug therapy of depression: benefits and limits of blood levels of tricyclic antidepressants]
Journal
Schweiz Med Wochenschr
Author(s)
Baumann Pierre
ISSN
0036-7672 (Print)
ISSN-L
0036-7672
Publication state
Published
Issued date
1981
Volume
111
Number
7
Pages
228-39
Language
french
Notes
Baumann, P
fre
English Abstract
Review
SWITZERLAND
1981/02/14
Schweiz Med Wochenschr. 1981 Feb 14;111(7):228-39.
Abstract
The introduction of sensitive methods has rendered possible a multitude of studies on the relationship between plasma levels of tricyclics and their clinical effectiveness. However, there are conflicting reports concerning the existence of a "therapeutic window" for the usual antidepressives such as amitriptyline, nortriptyline, chlorimipramine, imipramine, desipramine and maprotiline. The dosage is not indicated routinely but may provide useful hints when the patient does not respond to treatment or does not take the prescribed medication regularly (non-compliance). Plasma measurements of tricyclics have served to investigate the interaction of other drugs, the advantages of single or multiple dosage, the influence of the patient's age and sex and the existence of active metabolites. Other questions have been raised concerning the real efficacy of the drugs, and also concerning the type of depression which responds to this treatment.
Keywords
Antidepressive Agents, Tricyclic/blood/*therapeutic use, Biotransformation, Delayed-Action Preparations, Depression/*drug therapy, Dose-Response Relationship, Drug, Half-Life, Humans
Pubmed
Create date
11/01/2021 12:34
Last modification date
24/01/2021 7:26
Usage data